



2004-12-30

CMA Microdialysis has as one of the first biotechnology companies in Scandinavia obtained certificate for the ISO13485:2003 quality standard.

CMA Microdialysis, the pioneer in developing the microdialysis technique for monitoring tissue chemistry, today used in intensive care units for detecting early signs of life threatening ischemic conditions, has successfully upgraded the quality management system to the most current standard, ISO 13485:2003.

This is a new stand-alone standard based on ISO 9001:2000, where particular requirements for medical devices have been added, with the intention to harmonize with international regulatory requirements.

This means that we now have a process oriented management system with customer focus, to provide utmost quality and security for patients and medical staff when using the Microdialysis instruments and consumables.

CMA has previously quality system certificates in place for the products CE marked according to the medical device directive and also implemented the quality system requirements of the U.S regulations for the FDA 510(k)-cleared "Cerebral Microdialysis Tissue Monitoring System".

About CMA

CMA Microdialysis is the leading company devoted to the development, manufacturing and marketing of the Microdialysis technique. The company was formed in 1984 and was the first company in the world to market Microdialysis products and know-how. Consumables, instruments and computer software are sold to universities, hospitals and pharmaceutical companies as unique tools for *in vivo* sampling of organs and tissues. CMA has offices in Sweden, USA and Germany and a total of 60 employees